PT  - JOURNAL ARTICLE
AU  - Priego-Parra, Bryan Adrián
AU  - Triana-Romero, Arturo
AU  - Pinto-Gálvez, Samanta Mayanin
AU  - Ramos, Cristina Durán
AU  - Salas-Nolasco, Omar
AU  - Reyes, Marisol Manriquez
AU  - Ramos-de-la-Medina, Antonio
AU  - Remes-Troche, Jose María
TI  - Anxiety, depression, attitudes, and internet addiction during the initial phase of the 2019 coronavirus disease (COVID-19) epidemic: A cross-sectional study in México
AID  - 10.1101/2020.05.10.20095844
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.10.20095844
4099  - http://medrxiv.org/content/early/2020/05/15/2020.05.10.20095844.short
4100  - http://medrxiv.org/content/early/2020/05/15/2020.05.10.20095844.full
AB  - Objectives To describe the prevalence and distribution of anxiety and depression among Mexican population, and to examine its association with internet addiction during the COVID-19 outbreak.Design A web-based cross-sectional study.Setting General population in México.Participants 561 subjects were recruited (71% female, mean age 30.7 ± 10.6 years).Interventions An online survey to assess personal attitudes and perceptions towards COVID-19, sleep-disorders related, the Mexican version of the Hospital Anxiety and Depression Scale (HADS) and the Internet Addiction Test (IAT) was applied.Primary and secondary outcome measures Prevalence of anxiety, depression, internet addiction and sleep disorders and associated factors. Also, prevalence for anxiety and depression were compared to an historic control group.Results During the initial phase of the COVID-19 pandemic the prevalence for anxiety and depression was 50% (95% CI, 45.6% to 54.1%) and 27.6%, (95% CI 23.8% to 31.4%), respectively. We found a 51% (33% to 50%) increase in anxiety and up to 86% increase in depression during the initial weeks of the lock-down compared to the control group. According to the IAT questionnaire, 62.7% (95% CI 58.6% to 68.8%) of our population had some degree of internet addiction. Odds ratio for development of anxiety symptoms was 2.02 (95% CI1.56-2.1, p=0.0001) and for depression was 2.15 (95% CI 1.59-2.9, p=0.0001). In the multivariate analysis, younger age (p=0.006), sleep problems (p=0.000), and internet addiction (p=0.000) were associated with anxiety and depression.Conclusions Our study provides valuable information on the psychological impact that the COVID-19 pandemic has had on the Mexican population. As in other parts of the globe, in Mexico, fear of SARS-CoV-2 infection has had devastating consequences on mental health, such as anxiety, depression and sleeping disturbances. Internet abuse and the consequent overexposure to rapidly spreading misinformation (infodemia) are associated to anxiety and depression.Strengths and limitations of this studyOur study have addressed the immediate psychological effect of the pandemic in the general population in a Latin American country, specifically in Mexico, a nation with high population density.Using the IAT (a specific tool to assess internet dependency), we found internet addiction was highly prevalent and correlated to anxiety and depression.We used the snowball sampling strategy; thus, our population is biased and may not reflect the actual pattern of general population.We decided to compare anxiety and depression with an historic cohort, and although this control group is not exactly matched to our studied population, the prevalence of anxiety and mood disorders are like those reported previously in Mexico.Other limitations include response bias due to fewer older subjects participating, the fact that sleep problems were not rigorously evaluated with a specific tool, and some states in our country were not represented in this work.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset analyzed to generate the findings for this study are available from the corresponding author on reasonable request.